Peak Pharmaceuticals Develops Market Entry Strategy and Plan Aided by Outstanding Executive MBA Teams
Working under the auspices of the 2014 Executive Multidisciplinary Action Program at the Stephen M. Ross School of Business at the University of Michigan, two teams of Executive MBA (EMBA) students were engaged in September, 2014 to carry out a three month project in close collaboration with Peak Pharmaceuticals as industry partner. The research included a detailed analysis of the nutraceutical sector and preparation of three-year market entry strategies for hemp-based products targeting human and animal health channel markets.
The project scope included assessment and situational analysis of the target market domains including customer segments and channels, an in depth study of the competitive landscape, and a strategy for aggressively entering these markets.
Both EMBA teams delivered their final reports in December, including executive summaries, as well as base case product launch strategies along with a detailed analysis of the company, competitors, customers, collaborators and context (5C’s) across the U.S. nutraceutical/medical hemp market. Additional details included an analysis of segmentation, targeting and positioning, pricing policies, route to market and gaps within current strategies.
The deliverables further included (where applicable) survey results of key interviewees from relevant industries and consumer groups, and culminated with a 3-year plan for proposed activities with potential extended “blue sky” strategies.
Peak Pharmaceuticals President and CEO Dr. Soren Mogelsvang states, “We were thrilled and gratified by the opportunity to work with the very enthusiastic and professional executives that comprised our two teams. Through this relationship with the Stephen M. Ross School of Business at the University of Michigan, we gained access to invaluable resources, typically beyond the reach of smaller companies such as ours. We are really pleased to have such well-researched and detailed ‘roadmaps’ for our ongoing business development activities, aiding both our Canna-Pet™ sales and, perhaps more importantly, with our future aims for human CBD products. This will undoubtedly save tens of thousands of dollars down the road and accelerate our market entry. The information at hand is far more in-depth than pretty much any business plan I’ve ever seen before, and it will serve us very well as we continue to build Peak Pharma into a profitable and sustainable nutraceutical company. I’d like to personally thank the leadership at the Ross School and again offer my heartfelt thanks to both teams for an excellent and well done job.”
Additional details of the Company’s business, finances, appointments and agreements can be found as part of the Company’s continuous public disclosure as a reporting issuer with the Securities and Exchange Commission (“SEC”) available at www.sec.gov. For more information please visit www.peakpharma.com.
About Peak Pharmaceuticals, Inc. (OTCQB: CTCO)
Peak Pharmaceuticals, Inc. specializes in the development, manufacturing, sales and marketing of pharmaceutical-grade, hemp-based nutraceutical and supplement products for the human and animal health markets. The company aims to become a global leader in the research, development, sales and marketing of medicinal hemp and cannabinoid products. For more information visit www.peakpharma.com and follow us on Facebook, Twitter and LinkedIn.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the availability of additional funding; the early-stage nature of the industry sector; regulatory changes affecting the sale, transport or consumption of Cannabidiol or hemp based products by humans or animals; commercial impacts to the Company’s business, related agreements, product development, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC, including, the Company’s current reports on Form 8-K. The Company does not undertake to update these forward-looking statements. FDA Disclosure: The statements in this news release have not been evaluated by the Food and Drug Administration (FDA). The products and statements mentioned in this release are not intended for humans, or to diagnose, treat, cure, or prevent any disease.
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | email@example.com